本文对抗胸腺细胞球蛋白治疗中度至重度再生障碍性贫血(以下简称再障)的效果作了评价。抗胸腺细胞球蛋白治疗组21例患者,平均年龄33岁(9～69岁);对照组21例,平均年龄32岁(6～65岁),两组各有严重贫血14例。严重再障的标准是下列三项中至少具 This article evaluates the efficacy of anti-thymocyte globulin in the treatment of moderate to severe aplastic anemia (hereinafter referred to as aplastic anemia). Twenty-one patients in the anti-thymocyte globulin treatment group had an average age of 33 years (range, 9 to 69 years). In the control group, 21 patients (mean age, 32 years, aged 6 to 65 years) had severe anemia in both groups. The criteria for severe aplastic anemia are at least three of the following